Adma Biologics (ADMA) Cost of Revenue (2011 - 2025)

Adma Biologics has reported Cost of Revenue for 13 years, with the latest figure at -$162.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue fell 179.55% year-over-year to -$162.2 million; the trailing twelve-month figure through Dec 2025 stood at -$104.9 million (down 142.19% YoY), and the FY2025 full-year result was $4.8 million, down 97.66% from the prior year.
• Cost of Revenue for Q4 2025 stood at -$162.2 million, down from $1.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $203.9 million in Q4 2024, with the low at -$162.2 million in Q4 2025.
• Historically, Cost of Revenue has averaged $25.0 million across 5 years, with a median of $4.0 million in 2021.
• The largest YoY upside for Cost of Revenue was 5712.85% in 2025 against a maximum downside of 179.55% in 2025.
• Adma Biologics' Cost of Revenue stood at $71.6 million in 2021, then plunged by 49.98% to $35.8 million in 2022, then surged by 362.76% to $165.7 million in 2023, then grew by 23.08% to $203.9 million in 2024, then sank by 179.55% to -$162.2 million in 2025.
• The last three Cost of Revenue figures came in at -$162.2 million (Q4 2025), $1.3 million (Q3 2025), and $54.8 million (Q2 2025), per Business Quant data.